产品说明书
Bempedoic acid
 |
同义名 : | - |
| CAS号 : | 738606-46-7 | |
| 货号 : | A869454 | |
| 分子式 : | C19H36O5 | |
| 纯度 : | 98% | |
| 分子量 : | 344.486 | |
| MDL号 : | MFCD18800820 | |
| 存储条件： |
粉末 Inert atmosphere,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(304.8 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | ETC-1002 works as an AMPK activator. ETC-1002 at 100μM increased levels of AMPK phosphorylation in primary human MDMs exposure to LPS, and decreased production of proinflammatory cytokines and chemokines. In dyslipidemic subjects, ETC-1002 not only reduces plasma LDL cholesterol but also significantly attenuates levels of hsCRP, a clinical biomarker of inflammation. Silencing of LKB1 by siRNA could significantly abrogate AMPK phosphorylation and inhibitory effects of ETC-1002 on soluble mediators of inflammation. ETC-1002 suppressed thioglycollate-induced homing of leukocytes into mouse peritoneal cavity in vivo. Also, it restored adipose AMPK activity, reduced JNK phosphorylation, and diminished expression of macrophage-specific marker 4F/80 in a mouse model of diet-induced obesity. ETC-1002 is an investigational drug currently in Phase 2 development for treatment of dyslipidemia and other cardiometabolic risk factors[2]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.90mL 0.58mL 0.29mL |
14.51mL 2.90mL 1.45mL |
29.03mL 5.81mL 2.90mL |
| 参考文献 |
|---|